These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

745 related items for PubMed ID: 19700937

  • 1. Ovarian low-grade and high-grade serous carcinoma: pathogenesis, clinicopathologic and molecular biologic features, and diagnostic problems.
    Vang R, Shih IeM, Kurman RJ.
    Adv Anat Pathol; 2009 Sep; 16(5):267-82. PubMed ID: 19700937
    [Abstract] [Full Text] [Related]

  • 2. Molecular characterization of 103 ovarian serous and mucinous tumors.
    Vereczkey I, Serester O, Dobos J, Gallai M, Szakács O, Szentirmay Z, Tóth E.
    Pathol Oncol Res; 2011 Sep; 17(3):551-9. PubMed ID: 21136228
    [Abstract] [Full Text] [Related]

  • 3. The development of high-grade serous carcinoma from atypical proliferative (borderline) serous tumors and low-grade micropapillary serous carcinoma: a morphologic and molecular genetic analysis.
    Dehari R, Kurman RJ, Logani S, Shih IeM.
    Am J Surg Pathol; 2007 Jul; 31(7):1007-12. PubMed ID: 17592266
    [Abstract] [Full Text] [Related]

  • 4. Genetic alteration and immunohistochemical staining patterns of ovarian high-grade serous adenocarcinoma with special emphasis on p53 immnnostaining pattern.
    Lee SH, Kim H, Kim WY, Han HS, Lim SD, Kim WS, Kim S, Hwang TS.
    Pathol Int; 2013 May; 63(5):252-9. PubMed ID: 23714252
    [Abstract] [Full Text] [Related]

  • 5. Loss of p16INK4A expression in low-grade ovarian serous carcinomas.
    Schlosshauer PW, Deligdisch L, Penault-Llorca F, Fatemi D, Qiao R, Yao S, Pearl M, Yang Z, Sheng T, Dong J.
    Int J Gynecol Pathol; 2011 Jan; 30(1):22-9. PubMed ID: 21131838
    [Abstract] [Full Text] [Related]

  • 6. Defining the cut point between low-grade and high-grade ovarian serous carcinomas: a clinicopathologic and molecular genetic analysis.
    Ayhan A, Kurman RJ, Yemelyanova A, Vang R, Logani S, Seidman JD, Shih IeM.
    Am J Surg Pathol; 2009 Aug; 33(8):1220-4. PubMed ID: 19461510
    [Abstract] [Full Text] [Related]

  • 7. Clinicopathologic and Molecular Features of Paired Cases of Metachronous Ovarian Serous Borderline Tumor and Subsequent Serous Carcinoma.
    Chui MH, Xing D, Zeppernick F, Wang ZQ, Hannibal CG, Frederiksen K, Kjaer SK, Cope L, Kurman RJ, Shih IM, Wang TL, Vang R.
    Am J Surg Pathol; 2019 Nov; 43(11):1462-1472. PubMed ID: 31343420
    [Abstract] [Full Text] [Related]

  • 8. Is Invasive Micropapillary Serous Carcinoma a Low-grade Carcinoma?
    Ohishi Y, Imamura H, Aman M, Shida K, Kaku T, Kato K, Oda Y.
    Int J Gynecol Pathol; 2016 Jan; 35(1):56-65. PubMed ID: 26166721
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Genomic classification of serous ovarian cancer with adjacent borderline differentiates RAS pathway and TP53-mutant tumors and identifies NRAS as an oncogenic driver.
    Emmanuel C, Chiew YE, George J, Etemadmoghadam D, Anglesio MS, Sharma R, Russell P, Kennedy C, Fereday S, Hung J, Galletta L, Hogg R, Wain GV, Brand A, Balleine R, MacConaill L, Palescandolo E, Hunter SM, Campbell I, Dobrovic A, Wong SQ, Do H, Clarke CL, Harnett PR, Bowtell DD, deFazio A, Australian Ovarian Cancer Study (AOCS).
    Clin Cancer Res; 2014 Dec 15; 20(24):6618-30. PubMed ID: 25316818
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. KRAS (but not BRAF) mutations in ovarian serous borderline tumour are associated with recurrent low-grade serous carcinoma.
    Tsang YT, Deavers MT, Sun CC, Kwan SY, Kuo E, Malpica A, Mok SC, Gershenson DM, Wong KK.
    J Pathol; 2013 Dec 15; 231(4):449-56. PubMed ID: 24549645
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. BRAF mutation is associated with a specific cell type with features suggestive of senescence in ovarian serous borderline (atypical proliferative) tumors.
    Zeppernick F, Ardighieri L, Hannibal CG, Vang R, Junge J, Kjaer SK, Zhang R, Kurman RJ, Shih IeM.
    Am J Surg Pathol; 2014 Dec 15; 38(12):1603-11. PubMed ID: 25188864
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. [Clinicopathologic study and immunohistochemistry comparison of Pax2, p53 and Ki-67 in low- and high-grade ovarian serous carcinomas].
    Shen XX, Yu L, Bi R, Yang WT.
    Zhonghua Bing Li Xue Za Zhi; 2011 Aug 15; 40(8):511-6. PubMed ID: 22169637
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 38.